Capital raised by Newleos Therapeutics
1 Form D filing · first filed Feb 2025 · Boston, MA
President and CEO
Signatory on Newleos Therapeutics's Form D filings · $93.4M raised across 1
David Donabedian is on file as President and CEO at Newleos Therapeutics in Boston, MA. Newleos Therapeutics has 1 Form D filing on record, $93.4M raised in total. David Donabedian appears as a signatory on the company's filings.
NTX-1955 is a groundbreaking GABA A -γ1 selective positive allosteric modulator that represents the company's lead clinical program aimed at treating anxiety disorders. This molecule is designed to help mitigate anxiety symptoms with potentially fewer side effects compared to traditional therapies.
